GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
The SARS-CoV2 (COVID-19) pandemic and uncertainties in developing a vaccine have created an urgent need for new therapeutic approaches. A key question is whether it is possible to make rational predictions of new therapies based on the presently available scientific and medical information. In this...
Main Author: | Christopher E. Rudd |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01638/full |
Similar Items
-
Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study
by: Shi-Wei Yin, et al.
Published: (2021-06-01) -
IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01) -
Correlation analysis of percentages of T lymphocyte subsets and CD4+CD25+ regulatory T cells and HBV DNA level in peripheral blood of chronic hepatitis B patients
by: LI Caidong
Published: (2015-04-01) -
CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study
by: Joan Calvet, et al.
Published: (2020-11-01) -
AGE-DEPENDENT CHANGES OF T-REGULATORY AND Th17 SUBSET LEVELS IN PERIPHERAL BLOOD FROM HEALTHY HUMANS
by: A. P. Toptygina, et al.
Published: (2017-08-01)